Evidence map›Paper›PMID 24995301›Full record

ArticleBioMed research international2014

Peripheral injection of SB203580 inhibits the inflammatory-dependent synthesis of proinflammatory cytokines in the hypothalamus.

Andrzej P Herman, Agata Krawczyńska, Joanna Bochenek, Hanna Antushevich, Anna Herman, Dorota Tomaszewska-Zaremba

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Anandamide Influences Interleukin-1β Synthesis andAnimals : an open access journal from MDPI · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Andrzej P HermanPolish Academy of Sciences, The Kielanowski Institute of Animal Physiology and Nutrition, 05-110 Jabłonna, Poland.
Agata KrawczyńskaPolish Academy of Sciences, The Kielanowski Institute of Animal Physiology and Nutrition, 05-110 Jabłonna, Poland.
Joanna BochenekPolish Academy of Sciences, The Kielanowski Institute of Animal Physiology and Nutrition, 05-110 Jabłonna, Poland.ORCID 0000-0002-0821-0059
Hanna AntushevichPolish Academy of Sciences, The Kielanowski Institute of Animal Physiology and Nutrition, 05-110 Jabłonna, Poland.
Anna HermanThe Academy of Cosmetics and Health Care, 13 Podwale Street, 00-252 Warsaw, Poland.ORCID 0000-0002-2722-6195
Dorota Tomaszewska-ZarembaPolish Academy of Sciences, The Kielanowski Institute of Animal Physiology and Nutrition, 05-110 Jabłonna, Poland.ORCID 0000-0002-2619-4638
Kielanowski Institute of Animal Physiology and Nutrition · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study was designed to determine the effects of peripheral injection of SB203580 on the synthesis of interleukin- (IL-) 1β, IL-6, and tumor necrosis factor (TNF) α in the hypothalamus of ewes during prolonged inflammation. Inflammation was induced by the administration of lipopolysaccharide (LPS) (400 ng/kg) over 7 days. SB203580 is a selective ATP-competitive inhibitor of the p38 mitogen-activated protein kinase (MAPK), which is involved in the regulation of proinflammatory cytokines IL-1β, IL-6 and TNFα synthesis. Intravenous injection of SB203580 successfully inhibited (P < 0.01) synthesis of IL-1β and reduced (P < 0.01) the production of IL-6 in the hypothalamus. The p38 MAPK inhibitor decreased (P < 0.01) gene expression of TNFα but its effect was not observed at the level of TNFα protein synthesis. SB203580 also reduced (P < 0.01) LPS-stimulated IL-1 receptor type 1 gene expression. The conclusion that inhibition of p38 MAPK blocks LPS-induced proinflammatory cytokine synthesis seems to initiate new perspectives in the treatment of chronic inflammatory diseases also within the central nervous system. However, potential proinflammatory effects of SB203580 treatment suggest that all therapies using p38 MAPK inhibitors should be introduced very carefully with analysis of all expected and unexpected consequences of treatment.

Indexed as

AnimalsGene Expression RegulationHumansHypothalamusImidazolesInflammationInjectionsInterleukin-1Interleukin-6LipopolysaccharidesProtein Kinase InhibitorsPyridinesRNA, MessengerSheepTumor Necrosis Factor-alphaImidazolesInterleukin-1Interleukin-6LipopolysaccharidesProtein Kinase InhibitorsPyridinesRNA, MessengerSB 203580Tumor Necrosis Factor-alpha

Identifiers

PMID24995301
PMCPMC4065737
OpenAlexW2141489477

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.